Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Proof of Concept Trial Investigating the Safety and Efficacy of the Neoadjuvant Triplet Olaparib, Durvalumab and Bevacizumab in Advanced FIGO Stage IV High Grade Serous Ovarian Cancer

NCT06650709 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT06650709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06650709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Proof of Concept Trial Investigating the Safety and Efficacy of the Neoadjuvant Triplet Olaparib, Durvalumab and Bevacizumab in Advanced FIGO Stage IV High Grade Serous Ovarian Cancer
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2024
Completion date
November 1, 2028
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer stage iv